nach oben

Erschienen in:

01.10.2007 | Thoracic Oncology

Limited Cardiotoxicity after Extensive Thoracic Surgery and Intraoperative Hyperthermic Intrathoracic Chemotherapy with Doxorubicin and Cisplatin

verfasst von: Eelco de Bree, MD, Serge van Ruth, MD, PhD, Carl E. Schotborgh, MD, Paul Baas, MD, PhD, Frans A. N. Zoetmulder, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 10/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

Recently, pleural mesothelioma has been treated by cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy with doxorubicin and cisplatin. The well-established cardiotoxicity of doxorubicin and distressing data from an animal study raised concern about its impact on cardiac function. In the present study, early cardiotoxicity of this treatment modality was prospectively analyzed.

Patients and Methods

In 13 pleural mesothelioma patients, cardiotoxicity was monitored by clinical examination, electrocardiography, Troponin levels, cardiac ultrasonography, and estimation of left ventricular ejection fraction (LVEF) by radionuclide ventriculography before and during the first 6 months after cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy with doxorubicin (25–54 mg/m²) and cisplatin (65–120 mg/m²).

Results

No clinical cardiac failure or treatment-related death was observed. In two patients transient atrial fibrillation was noted; one associated with pulmonary emboli. Early posttreatment Troponin release was not of predictive value. Ultrasonography did not reveal significant alterations. LVEF decreased significantly (mean 0.07 or 11%, P = .001) during the first 3 months and remained stable thereafter. In univariate analysis, the degree of LVEF reduction was statistically related to maximal intrathoracic doxorubicin concentration (P = .031) and total cisplatin dose (P = .029). Direct exposure of the heart to the drugs as a result of partial pericardectomy was not associated with greater LVEF decrease. On the contrary, partial pericardectomy seemed to be associated with a smaller LVEF decline than when the pericardium remained intact (P = .045). In this small series, no statistically significant correlation between other treatment or pharmacokinetic parameters and LVEF decline was found. Notably, higher doxorubicin plasma concentrations and exposure were not associated with increased LVEF reduction.

Conclusions

Early cardiotoxicity is limited after this treatment modality using substantial doses of doxorubicin and cisplatin. Hence, this study suggests that intrathoracic chemotherapy with doxorubicin and/or cisplatin may be used for primary and secondary pleural malignancies, even immediately after extensive thoracic surgery, without concern of severe early cardiotoxicity.

Tan C, Sedrakyan A, Browne J, et al. The evidence of the effectiveness of management for malignant pleural effusion: a systemic review. Eur J Cardiothorac Surg 2006; 29:829–38PubMedCrossRef

Witkamp AJ, de Bree E, van Goethem R, et al. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev 2001; 27:365–74PubMedCrossRef

de Bree E, van Ruth S, Baas P, et al. Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest 2002; 121:480–7PubMedCrossRef

van Ruth S, Baas P, Haas RLM, et al. Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma. Ann Surg Oncol 2003; 10:176–82PubMedCrossRef

Monneuse O, Beaujard AC, Guibert B, et al. Long-term results of intrathoracic chemohyperthermia (ITCH) for the treatment of pleural malignancies. Br J Cancer 2003; 88:1839–43PubMedCrossRef

Matsuzaki Y, Shibata K, Yoshioka M, et al. Intrapleural perfusion hyperthermo-chemotherapy for malignant pleural dissemination and effusion. Ann Thorac Surg 1995; 59:127–31PubMedCrossRef

Yellin A, Simansky DA, Paley M, et al. Hyperthermic pleural perfusion with cisplatin. Early clinical experience. Cancer 2001; 92:2197–203PubMedCrossRef

Ratto GB, Civalleri D, Espositi M, et al. Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic study. J Thorac Cardiovasc Surg 1999; 117:759–65PubMedCrossRef

Rafaely Y, Simansky DA, Paley M, et al. Resection and perfusion thermochemotherapy: a new approach for the treatment of thymic malignancies with pleural spread. Ann Thorac Surg 2001; 72:366–70CrossRef

10.

Shigemura N, Akashi A, Nakagiri T, et al. Pleural perfusion thermo-chemotherapy under VATS: a new less invasive modality for advanced lung cancer with pleural spread. Ann Thorac Surg 2004; 77:1016–22PubMedCrossRef

11.

Fujimara T, Yonemura Y, Nojima N, et al. Intrathoracic hyperthermochemotherapeutic perfusion for intrathoracic malignancies in gastric cancer. Hepatogastroenterology 1995; 42:878–84

12.

Richards WG, Zellos L, Bueno R, et al. Phase I to II study of pleurectomy / decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 2006; 24:1561–7PubMedCrossRef

13.

van Ruth S, van Tellingen O, Korse CM, et al. Pharmacokinetics of doxorubicin and cisplatin used in intraoperative hyperthermic intrathoracic chemotherapy after cytoreductive surgery for malignant pleural mesothelioma and pleural thymoma. Anticancer Drugs 2003; 14:57–65PubMedCrossRef

14.

Elisson LO, Bjorkman S. Congestive heart failure in rabbits after a single intrapleural administration of a low dose of doxorubicin or epirubicin. Pharmacol Toxicol 1988; 62:84–9PubMed

15.

Schimmel KJM, Richel DJ, van den Brink RBA, et al. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 2004;30:181–91PubMedCrossRef

16.

Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91:710–7

17.

Danesi R, Fogli S, Gennari A, et al. Pharmacokinetic – pharmacodynamic relationship of the anthracycline anticancer drugs. Clin Pharmacokinet 2002; 41:431–44PubMedCrossRef

18.

Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents. Incidence, treatment, and prevention. Drug Safety 2000; 22:304–9CrossRef

19.

Swain M, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer 2003; 97:2869–79PubMedCrossRef

20.

Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998;25 (suppl 10):72–85PubMed

21.

Icli F, Karaoguz H, Dincol D, et al. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer 1993; 15:587–93CrossRef

22.

Doll Dc, List AF, Greco FA, et al. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med 1986; 105:48–51PubMed

23.

Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18:1725–32PubMed

24.

Lu P. Monitoring cardiac function in patients receiving doxorubicin. Semin Nucl Med 2005; 35:197–201PubMedCrossRef

25.

Ng R, Better N, Green MD. Anticancer agents and cardiotoxicity. Semin Oncol 2006; 33:2–14PubMedCrossRef

26.

Herman EH, Zhang J, Lipshultz S, et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999; 17:2237–43PubMed

27.

Cardinale D, Sandri M, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109:2749–54PubMedCrossRef

28.

Lipshultz SE, Rifai N, Sallan SE, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997; 96:2641–8PubMed

29.

Sandri MT, Cardinale D, Zorzino L, et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem 2003; 49:248–52PubMedCrossRef

30.

Kremer LC, Bastiaansen BA, Offringa M, et al. Troponin T in the first 24 hours after the administration of chemotherapy and the detection of myocardial damage in children. Eur J Cancer 2002; 38:686–9PubMedCrossRef

31.

Koseoglu V, Berberoglou S, Karademir S, et al. Cardiac troponin I: is it a marker to detect cardiotoxicity in children treated with doxorubicin. Turk J Pediatr 2005; 47:17–22PubMed

32.

Mathew P, Suarez W, Kip K, et al. Is there a role for serum cardiac troponin I as a marker for myocardial dysfunction in pediatric patients receiving anthracycline-based therapy? A pilot study. Cancer Invest 2001; 19:352–9PubMedCrossRef

33.

Auner HW, Tinchon C, Linkesch W, et al. Prolonged monitoring of troponin T for the detection of anthracycline Cardiotoxicity in adults with haematological malignancies. Ann Hematol 2003; 82:218–22PubMed

34.

Kismet E, Varan A, Ayabakan C, et al. Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin. Pediatr Blood Cancer 2004; 42:220–4PubMedCrossRef

35.

Urano M, Kuroda M, Nishimura Y. For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia 1999; 15:79–107PubMedCrossRef

36.

Urano M, Begley J, Reynolds R. Interaction between adriamycin cytotoxicity and hyperthermia: growth-phase-dependent thermal sensitization. Int J Hyperthermia 1994; 10:817–26PubMed

37.

Goldstein LS, Dewhirst MW, Repacholi M, Kheifets L. Summary, conclusions and recommendations: adverse temperature levels in the human body. Int J Hyperthermia 2003; 19:373–84PubMedCrossRef

38.

Dewhirst MW, Viglianti BL, Lora-Michelis M, et al. Basic principles of thermal dosimetry and thermal thresholds for tissue damage from hyperthermia. Int J Hyperthermia 2003; 19:267–94PubMedCrossRef

39.

Nagaoka S, Kawasaki S, Sasaki K, et al. Intracellular uptake, retention and cytotoxic effect of adriamycin combined with hyperthermia in vitro. Jpn J Cancer Res 1986; 77:205–11PubMed

40.

Los G, Sminia P, Wondergem J, et al. Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer 1991; 27:472–7PubMedCrossRef

41.

Sesan S. Indications and limitations of radiotherapy in malignant pleural mesothelioma. Curr Opinion Oncol 2003; 15:144–7CrossRef

42.

Boutin C, Rey F, Viallat J-R. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 1995; 108:754–8PubMed

43.

Cuzick J, Stewart H, Rutquist L, et al. Cause specific mortality in long term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 1994; 12:447–53PubMed

44.

Marks L, Yu X, Prosnitz RG, et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys 2005; 63:214–23PubMedCrossRef

45.

Ozols RF, Locker GY, Doroshow JH, et al. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 1979; 39:3209–14PubMed

46.

van der Vaart PJM, van der Vange N, Zoetmulder FAN, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 1998; 34:148–54PubMedCrossRef

Titel: Limited Cardiotoxicity after Extensive Thoracic Surgery and Intraoperative Hyperthermic Intrathoracic Chemotherapy with Doxorubicin and Cisplatin
verfasst von: Eelco de Bree, MD
Serge van Ruth, MD, PhD
Carl E. Schotborgh, MD
Paul Baas, MD, PhD
Frans A. N. Zoetmulder, MD, PhD
Publikationsdatum: 01.10.2007
Verlag: Springer-Verlag
Erschienen in: Annals of Surgical Oncology / Ausgabe 10/2007
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-007-9508-3

Neu im Fachgebiet Chirurgie

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Limited Cardiotoxicity after Extensive Thoracic Surgery and Intraoperative Hyperthermic Intrathoracic Chemotherapy with Doxorubicin and Cisplatin